Eun-kyung Jung “Try to hire 2 out of 3 pharmaceutical companies that promise to supply vaccines before the end of the year”

▶ Click here to enlarge

Jung Eun-kyung, head of the Central Defense Countermeasures Headquarters (Bang Dae-bon), said: “At least two or more are aiming to complete the contract by the end of the year in connection with the negotiations on the advance purchase of a new vaccine against coronavirus infection (Corona 19). “Review consultation is ongoing.”

General Manager Jung answered the related questions in the regular briefing that day.

The government previously announced a total of 44 million vaccines, including 10 million people through the installation of COVAX, an international project for the joint purchase and distribution of vaccines, and 34 million through individual negotiations with global pharmaceutical companies. He announced a plan to secure it.

Among them, four pharmaceutical companies that have already agreed to advance purchase are AstraZeneca from the United Kingdom, Pfizer, Johnson & Johnson, Janssen and Modena from the United States.

The contract with AstraZenekawa has now been completed and the purchase amount has been confirmed through legally binding agreements with Pfizer, Johnson & Johnson-Jansen (letter of purchase) and Modena (supply agreement).

“We continue to discuss additional amounts with pharmaceutical companies” regarding the government’s advocacy to secure an additional number of vaccines in addition to 44 million people. “The additional amount has not yet been confirmed.” Said.

Regarding the fact that the executive director of the Democratic Party, Nak-yeon Lee, said the day before that ‘the vaccination of the crown 19 is trying to start before March next year’, he said that “the AstraZeneca vaccine (developed ) is also produced in Korea and is the best in terms of delivery time. It is expected to be fast, “he said.” Of course, other vaccines are still negotiating the delivery time.

He continued: “With regard to the approval of the vaccine, the FDA has reviewed the clinical approval process of the European Union (EU) and the verification process of the World Health Organization (WHO) and managed by the Ministry of Safety of Food and Medicines. We are preparing together to make it possible, “he added.

Regarding the development status of COVID-19 home treatment, Jung said: “I know we are looking at the data after the current phase 2 clinical trial for antibody treatments.”

He said: “In the case of antibody therapy, if given early on, it is expected to have the effect of preventing a ‘severe progression’ that progresses to severe and leads to death.

[연합뉴스]

Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited